Fox Run Management L.L.C. Purchases New Position in ICU Medical, Inc. (NASDAQ:ICUI)

Fox Run Management L.L.C. acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,591 shares of the medical instruments supplier’s stock, valued at approximately $712,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Harvest Fund Management Co. Ltd purchased a new position in shares of ICU Medical in the fourth quarter worth $33,000. Point72 Hong Kong Ltd purchased a new position in ICU Medical in the 3rd quarter worth about $72,000. Venturi Wealth Management LLC lifted its stake in ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after acquiring an additional 206 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of ICU Medical by 166.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 907 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 567 shares during the last quarter. Finally, Coldstream Capital Management Inc. bought a new stake in shares of ICU Medical in the third quarter worth approximately $227,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Down 0.7 %

Shares of ICUI stock opened at $147.07 on Monday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12 month low of $93.36 and a 12 month high of $196.26. The stock has a market cap of $3.61 billion, a P/E ratio of -32.18 and a beta of 0.73. The company has a 50 day simple moving average of $156.08 and a two-hundred day simple moving average of $164.43.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Raymond James set a $97.00 price objective on shares of ICU Medical in a research report on Wednesday, March 12th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Tuesday, March 18th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $168.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.